Gamma Knife Market Set for Robust Growth USD 776.3 Million by 2035 amidst Rising Neurological Cases and Preference for Non-Invasive Treatment | FMI

The global gamma knife market is poised for substantial expansion between 2025 and 2035, driven by the growing incidence of neurological disorders and the increasing preference for non-invasive treatment modalities. With Gamma Knife radiosurgery establishing itself as a cutting-edge, precision-focused tool in treating complex brain conditions, the market is projected to grow from USD 390.9 million in 2025 to USD 776.3 million by 2035, at a compound annual growth rate (CAGR) of 7.6%.

Gamma Knife radiosurgery—a highly advanced form of stereotactic radiosurgery (SRS)—is increasingly becoming the treatment of choice for brain tumors, arteriovenous malformations (AVMs), and functional brain disorders such as trigeminal neuralgia. Unlike traditional open-brain surgeries, this technique focuses gamma radiation beams directly at the affected tissue, minimizing damage to surrounding healthy brain structures and substantially reducing recovery time.

Stay Updated with Market Movements: Get Your Sample Report! https://www.futuremarketinsights.com/report-sample#5245502d47422d353839

Key Drivers of Growth

The Gamma Knife market’s ascent can be attributed to:

• A global rise in neurological disorders and brain metastases
• Increased patient preference for non-invasive treatments
• Technological advances in imaging, AI-assisted treatment planning, and robotic integration
• Improved healthcare infrastructure and rising medical expenditures across emerging and developed economies
• Widespread insurance coverage and reimbursement policies, particularly in countries like the U.S.

Regional Insights:

United States: Leading Innovation and Adoption

The U.S. market is witnessing strong momentum, expected to grow at a CAGR of 7.4% between 2025 and 2035. The increasing number of companies offering Gamma Knife solutions, along with an alarming rise in brain tumor diagnoses—over 700,000 Americans currently live with brain tumors—are critical contributors to this growth.

Major cancer treatment hubs such as Mayo Clinic, Cleveland Clinic, and MD Anderson Cancer Center are increasingly incorporating Gamma Knife procedures, driven by the precision it offers in targeting lesions to sub-millimeter accuracy. Additionally, the integration of AI in radiosurgical planning tools is enhancing patient outcomes, and the expanding insurance coverage by Medicare and private payers is accelerating patient access.

United Kingdom: NHS-Led Technological Expansion

In the UK, the market is set to expand at a CAGR of 7.0% over the forecast period. The National Health Service (NHS) is playing a pivotal role in expanding the country’s Gamma Knife infrastructure, especially in tertiary hospitals.

With over 12,000 brain tumors diagnosed annually, and a growing pool of patients with trigeminal neuralgia and AVMs, the demand for non-invasive neurosurgical interventions is surging. AI-powered imaging tools are not only increasing surgical precision but also supporting the shift towards outpatient-based radiosurgery—particularly beneficial for elderly and high-risk patients.

European Union: Government Backing and AI Integration

The EU Gamma Knife market is projected to grow at a CAGR of 7.1% from 2025 to 2035, fueled by increasing government investments in cancer research and precision therapy. Programs like Horizon Europe have earmarked EUR 5 billion for advancing radiotherapy and cancer care technologies.

Countries such as Germany, France, and Italy are at the forefront of this expansion, with specialized hospitals embracing digital twin technologies and AI for improved radiosurgical outcomes. Additionally, cross-border healthcare collaborations within the EU are enabling patients from underserved regions to access cutting-edge treatments.

Japan: Addressing an Aging Nation

With a rapidly aging population—over 28% aged 65 or older—Japan’s Gamma Knife market is expected to expand at a CAGR of 7.3% through 2035. The government’s massive funding of ¥250 billion into radiotherapy and neurodegenerative disease research is propelling the country’s neurosurgical capabilities.

Japanese medical centers are deploying AI-powered Gamma Knife systems integrated with high-precision imaging, facilitating superior targeting and real-time monitoring. This allows for more personalized treatment plans with fewer side effects and enhanced survival outcomes.

South Korea: Embracing AI and Digital Health

In South Korea, the Gamma Knife market is predicted to grow at a CAGR of 7.4%, supported by investments of ₩1.8 trillion from the Ministry of Health and Welfare. The country’s proactive stance on digital healthcare and neural surgery innovation is transforming radiosurgery into a precision-based discipline.

Leading hospitals are adopting AI-assisted treatment planning combined with robotic delivery systems, resulting in better patient experiences and shorter hospital stays. The integration of real-time patient monitoring and long-term follow-ups ensures personalized treatment regimens, marking a step forward in modern neurosurgery.

Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trends! https://www.futuremarketinsights.com/reports/gamma-knife-market

Competitive Landscape

The Gamma Knife market is highly competitive, driven by both global field leaders and emerging players focusing on technological innovation. Companies are continually developing AI-enabled radiation planning systems, robotics integration, and web-connected treatment platforms to improve targeting precision and treatment safety.

Key Market Players:

• Elekta AB
• Varian Medical Systems
• Huiheng Medical, Inc.
• Akesis, Inc.
• MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
• American Radiosurgery Inc.
• Panacea Medical Technologies Pvt. Ltd.
• Nordion (Canada) Inc.
• Accuray Incorporated
• Hitachi, Ltd.

These companies are propelling the field forward with a focus on reduced procedural complications, patient-centric outcomes, and next-gen automation tools.

Market Segmentation

By Disease Indication:

• Brain Metastasis
• Cancer
• Arteriovenous Malformation (AVM)
• Trigeminal Neuralgia
• Others

By Anatomy:

• Head
• Neck
• Other Body Parts

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• East Asia
• South Asia Pacific
• Middle East and Africa

Download Our Comprehensive Healthcare Industry Report! https://www.futuremarketinsights.com/industry-analysis/radiation-therapy

Conclusion

The Gamma Knife market is entering a golden era of growth and innovation. As AI, robotics, and non-invasive technologies converge, patients with neurological conditions now have access to more accurate, effective, and safer treatment options than ever before. With expanding global healthcare investments, favorable policies, and rising awareness, the future of the Gamma Knife market looks both technologically promising and medically transformative.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube